title: [Association between the change regularity of peripheral blood mononuclear cell mitochondrial deoxyribonucleic acid content and human immunodeficiency virus-related lipodystrophy].
abstract: OBJECTIVE
  To investigate the change regularity of peripheral blood mononuclear cell (PBMC) mtDNA (mitochondrial deoxyribonucleic acid) content and its association with HIV-LD (human immunodeficiency virus-related lipodystrophy) in HAART (highly active antiretroviral therapy).
  
  
  METHODS
  At baseline, Months 6 and 24 of therapy, the cryopreserved PBMC were collected from 33 patients on a regular follow-up at our clinic. Among them, 17 had HIV-LD. Then total DNA was extracted and mtDNA content quantified by real-time PCR (polymerase chain reaction).
  
  
  RESULTS
  The HIV/AIDS patients had a lower content of PBMC mtDNA (2(-ΔΔCt)) than the healthy controls at baseline (9.578 vs 17.195, P < 0.01). The mtDNA content was lower in the HIV-LD group than that in the no LD (NLD) group at each time point of therapy (13.619 vs 5.775, 6.360 vs 1.387, 7.170 vs 1.266, all P < 0.05). In the HIV-LD group, the half- and 2-year PBMC mtDNA content was markedly lower than those at baseline (both P < 0.05). And the change of mtDNA content (within half a year) was earlier than the onset of clinical HIV-LD at one year later. In the NLD group, the PBMC mtDNA content have an insignificant change after therapy. The mtDNA content decreased significantly in stavudine (d4T)-containing regimen group after treatment (P < 0.01), but showed no significant change in zidovudine (AZT)-containing regimen group after therapy.
  
  
  CONCLUSIONS
  The decreased content of PBMC mtDNA after HIV infection and during HAART therapy is associated with HIV-LD. Nucleoside reverse transcriptase inhibitor, especially d4T, plays an important role in the progression of HIV-LD.
authors.affiliation: Department of Infectious Diseases, Chinese Academy of Medical Sciences, Beijing 100730, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Wu
authors.forename: Wei-bin
authors.initials: WB
authors.lastname: Gu
authors.forename: Lu
authors.initials: L
authors.lastname: Zhang
authors.forename: Yan-ling
authors.initials: YL
authors.lastname: Li
authors.forename: Zhi-feng
authors.initials: ZF
authors.lastname: Qiu
authors.forename: Yang
authors.initials: Y
authors.lastname: Han
authors.forename: Jing
authors.initials: J
authors.lastname: Xie
authors.forename: Tai-sheng
authors.initials: TS
authors.lastname: Li
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D016022:Case-Control Studies; D004272:DNA, Mitochondrial / Q000032:analysis* / Q000378:metabolism; D005260:Female; D039682:HIV-Associated Lipodystrophy Syndrome / Q000188:drug therapy / Q000235:genetics*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D018119:Stavudine / Q000627:therapeutic use; D055815:Young Adult; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D004272:DNA, Mitochondrial; D015215:Zidovudine; D018119:Stavudine